dc.contributor.author | Elshakei, Lujain | |
dc.date.accessioned | 2020-09-28T10:34:05Z | |
dc.date.available | 2020-09-28T10:34:05Z | |
dc.date.issued | 2020-03-12 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/2038 | |
dc.description | Complement system is classic pathway an?gen-an?body complexes ac?vate C1to
form protease which cleaves C2, C4 and C3 convertase which cleaves C3 this cascade
con?nue to C9, in order to stop this cascade C1 is inhibited by C1 esterase inhibitor
enzyme. deficiency in this enzyme can cause angioedema.(1)
Hereditary angioedema (HAE) is an autosomal dominant disease. caused by C1
esterase inhibitor deficiency. It is characterized by swelling episodes that affect the
skin or mucous membranes, gastrointes?nal tract and upper airways. Laryngeal
edema can be life threatening. Biochemical diagnosis can be established by
diminished C4 levels and low C1 inhibitor levels or func?on. Pa?ents with HAE type I
(85%) have reduced an?genic and func?onal C1 inhibitor levels, whereas pa?ents
with HAE type II (15%) show only a reduc?on in C1 inhibitor func?on. During the past
2 decades, the new estrogen-dependent inherited angioedema without C1 inhibitor
deficiency, also referred to as HAE type III. | en_US |
dc.description.abstract | Hereditary angioedema (HAE) is an autosomal dominant disease characterized by
recurrent angioedema episodes of life-threatening angioedema. A=acks of
angioedema in HAE pa?ents last 3 or more days, begin during childhood, and
con?nue to occur throughout life. Tragically, pa?ents with HAE con?nue to die as a
direct consequence of the disease. Minimizing the morbidity and mortality
associated with HAE requires both effec?ve treatment of acute a=acks as well as
strategies to prevent HAE a=acks. Treatment usually involves a combina?on of
prophylaxis, using androgens or an?fibroly?c drugs, and replacement with C'1
esterase inhibitor concentrate for acute a=acks and before surgery or other
trauma?c procedures.This review will recap the past treatment op?ons, review the
new current treatment op?ons, and discuss poten?al future treatment op?ons for
pa?ents with HAE. | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Current and future therapy of hereditary angioedema due to C1 inhibitor deficiency | en_US |
dc.type | Other | en_US |